Åpne denne publikasjonen i ny fane eller vindu >>Uppsala universitet, Science for Life Laboratory, SciLifeLab. Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaci. Strike Pharm AB, Uppsala, Sweden.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaci. Uppsala universitet, Science for Life Laboratory, SciLifeLab. Strike Pharm AB, Uppsala, Sweden.
Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
Strike Pharm AB, Uppsala, Sweden.;Scicross AB, Skövde, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Strike Pharm AB, Uppsala, Sweden..
Uppsala universitet, Science for Life Laboratory, SciLifeLab. Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaci. Strike Pharm AB, Uppsala, Sweden.
Vise andre…
2024 (engelsk)Inngår i: Nature Communications, E-ISSN 2041-1723, Vol. 15, nr 1, artikkel-id 9542Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named BiA9*2_HF, that allows for rapid antibody-peptide conjugate formation. The format is designed to facilitate peptide antigen delivery to CD40 expressing cells combined with simultaneous CD40 agonistic activity. In vivo, the selected bispecific antibody BiA9*2_HF loaded with peptide cargos induces improved antigen-specific proliferation of CD8+ (10-15 fold) and CD4+ T cells (2-7 fold) over control in draining lymph nodes. In both virus-induced and neoantigen-based mouse tumor models, BiA9*2_HF demonstrates therapeutic efficacy and elevated safety profile, with complete tumor clearance, as well as measured abscopal impact on tumor growth. The BiA9*2_HF drug candidate can thus be utilized to tailor immunotherapeutics for cancer patients.
sted, utgiver, år, opplag, sider
Springer Nature, 2024
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-543865 (URN)10.1038/s41467-024-53839-5 (DOI)001348514000014 ()39500897 (PubMedID)2-s2.0-85208602407 (Scopus ID)
Forskningsfinansiär
Uppsala UniversityVinnova, 2021-02640Vinnova, 2017-02105Vinnova, 2016-05181Knut and Alice Wallenberg Foundation, 2020.0182Swedish Cancer Society, 22 2219 PjScience for Life Laboratory, SciLifeLabSwedish Society for Medical Research (SSMF), S15-0065Vinnova, 2019-00048
Merknad
De två första författarna delar förstaförfattarskapet
De två sista författarna delar sistaförfattarskapet
2024-11-282024-11-282025-04-05bibliografisk kontrollert